Since Rad52 deletion in mice results only in mild phenotype without major impact on HR, and a peptide aptamer targeting RAD52 did not exert any detectable side effects in mice, RAD52 appears to be a promising target to trigger synthetic lethality in BRCA-deficient tumor cells without affecting normal cells [10, 11]. Here, RAD52 is linked to neoplasm.